https://www.selleckchem.com/pr....oducts/mpp-iodide.ht
This study aimed to assess the processes and clinical outcomes of a joint collaboration between Antimicrobial Stewardship Program (ASP) and the outpatient parenteral antimicrobial therapy (OPAT) unit for delivery of monoclonal antibody therapy for mild-to-moderate COVID-19. We carried out a retrospective, interim analysis of our COVID-19 monoclonal antibody therapy program. Outcomes included clinical response, incidence of hospitalization, and adverse events. A total of 175 patients (casirivimab-imdevimab, n=130; bamlanivimab, n=45)
Like
Comment
Share
